

NV Department of Health and Human Services

Drug Transparency Technical Guidelines

Drug Manufacturer Significant Price Increase Reporting Instructions

Version (v): 11/15/2019; Supersedes: 01/09/2019; 07/13/2018

NRS 439B.640

Reporting Date: On or before April 1
Reporting Frequency: Annually
Form Template Name: "Drug Manufacturer Price Increase Reporting _template vmm.dd.yy"

Purpose: NRS 439B.640 requires that manufacturers of prescription drugs that appear on the most current list compiled by the Nevada Department of Health and Human Services (DHHS) report on factors that contributed to a significant increase in price with an explanation of each factor's role in the price increase; and any other information as prescribed.

Reporting Requirements Detailed in NRS 439B.640 can be found at the following link:

<https://www.leg.state.nv.us/NRS/NRS-439B.html#NRS439BSec640>

Instructions:

1. DHHS's excel template provides manufacturers with a standardized form that incorporates all the fields required by law.
2. All fields listed in the template document are required fields, unless otherwise noted.
3. The departmental template headers should not be rearranged or changed in any way.
4. All values should be reported at the National level unless otherwise noted.
5. If prices increased for all formulations, dosages, and packaging variants of one drug due to identical factors, drug manufacturers can submit one report per drug. Each National Drug Code (NDC) for which price increase factors are described should be listed in the report under the "NDC(s) (format XXXXX-XXXX-XX)" field. If more than one NDC is included in a cell, each NDC should be separated by a semicolon.
6. For each drug reported, the manufacturer may report as many factors as required to justify the price increase. The total "% Influence of Factors" for each drug should equal 100%.
7. In describing the factor and explaining its role in the price increase, a detailed explanation should be utilized. Incomplete or overly vague responses and responses indicating that this information is not available will be deemed noncompliant. For example, a response indicating "market conditions" or "market dynamics" is not sufficiently detailed. If "market conditions" were responsible for a price increase, a manufacturer would need to specifically describe what market conditions were responsible for the price increase and outline in detail why these impacted the price.
8. For reports or technical assistance, send your questions or submissions to:
drugtransparency@dhhs.nv.gov